Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats

被引:88
作者
de Wilt, JHW [1 ]
Manusama, ER [1 ]
van Tiel, ST [1 ]
van Ijken, MGA [1 ]
ten Hagen, TLM [1 ]
Eggermont, AMM [1 ]
机构
[1] Univ Rotterdam Hosp, Dr Daniel Den Hoed Canc Ctr, Dept Surg Oncol, NL-3075 EA Rotterdam, Netherlands
关键词
TNF; melphalan; isolated limb perfusion; rats;
D O I
10.1038/sj.bjc.6990335
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
An isolated limb perfusion (ILP) model using soft tissue sarcoma-bearing rats was used to study prerequisites for an effective ILP, such as oxygenation of the perfusate, temperature of the limb, duration of the perfusion and concentration of tumour necrosis factor (TNF). Combination of 50 mu g TNF and 40 mu g melphalan demonstrated synergistic activity leading to a partial and complete response rate of 71%. In comparison to oxygenated ILP, hypoxia was shown to enhance anti-tumour activity of melphalan alone and TNF alone but not of their combined use. Shorter perfusion times decreased anti-tumour responses. At a temperature of 24-26 degrees C, anti-tumour effects were lost, whereas temperatures of 38-39 degrees C or 42-43 degrees C resulted in higher response rates. However, at 42-43 degrees C, local toxicity impaired limb function dramatically. Synergy between TNF and melphalan was lost at a dose of TNF below 10 mu g in 5 ml perfusate. We conclude that the combination of TNF and melphalan has strong synergistic anti-tumour effects in our model, just as in the clinical setting. Hypoxia enhanced activity of melphalan and TNF alone but not the efficacy of their combined use, For an optimal ILP, minimal perfusion time of 30 min and minimal temperature of 38 degrees C was mandatory. Moreover, the dose of TNF could be lowered to 10 mu g per 5 ml perfusate, which might allow the use of TNF in less leakage-free or less inert perfusion settings.
引用
收藏
页码:161 / 166
页数:6
相关论文
共 42 条
[1]   Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver [J].
Alexander, HR ;
Bartlett, DL ;
Libutti, SK ;
Fraker, DL ;
Moser, T ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1479-1489
[2]  
ASHER A, 1987, J IMMUNOL, V138, P963
[3]  
BENCKHUIJSEN C, 1988, EUR J SURG ONCOL, V14, P157
[4]  
BROUCKAERT P, 1992, LYMPHOKINE CYTOK RES, V11, P193
[5]   MELPHALAN UPTAKE, HYPERTHERMIC SYNERGISM AND DRUG-RESISTANCE IN A HUMAN CELL-CULTURE MODEL FOR THE ISOLATED LIMB PERFUSION OF MELANOMA [J].
CLARK, J ;
GRABS, AJ ;
PARSONS, PG ;
SMITHERS, BM ;
ADDISON, RS ;
ROBERTS, MS .
MELANOMA RESEARCH, 1994, 4 (06) :365-370
[6]  
de Vries MR, 1998, RECENT RES CANCER, V147, P107
[7]  
DEBOECK G, 1997, J HIGH RES CHROMAT, V20, P697
[8]   Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas - The cumulative multicenter European experience [J].
Eggermont, AMM ;
Koops, HS ;
Klausner, JM ;
Kroon, BBR ;
Schlag, PM ;
Lienard, D ;
vanGeel, AN ;
Hoekstra, HJ ;
Meller, I ;
Nieweg, OE ;
Kettelhack, C ;
BenAri, G ;
Pector, JC ;
Lejeune, FJ .
ANNALS OF SURGERY, 1996, 224 (06) :756-765
[9]   Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial [J].
Eggermont, AMM ;
Koops, HS ;
Lienard, D ;
Kroon, BBR ;
vanGeel, AN ;
Hoekstra, HJ ;
Lejeune, FJ .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) :2653-2665
[10]  
Eggermont AMM, 1996, CANCER SURV, V26, P335